NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits may be filed on behalf of shareholders of Caribou Biosciences, Inc. CRBUInspirato Incorporated ISPOKornit Digital Ltd. KRNTand Alico, Inc. ALCO. Shareholders have until the deadlines below to petition the court to be lead plaintiff. For more information on each case, see the link provided.

Caribou Biosciences, Inc. CRBU

Class Period: As per and/or traceable to the November 20, 2020 IPO; In accordance with and/or traceable to the SPO of March 18, 2021; November 20, 2020 – September 19, 2022

Lead Plaintiff Deadline: April 11, 2023

Caribou is a clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies for the treatment of hematological malignancies and solid tumors in the US and internationally. The Company is developing, among other product candidates, CB-010, an allogeneic anti-CD19 CAR T-cell therapy1, which is in a Phase 1 clinical trial termed “ANTLER” for the treatment of relapsed or refractory B-cell non- Hodgkin found lymphoma (“r/r B-NHL”).

According to the defendants, CB-010 is the first clinical-stage allogeneic anti-CD19 CAR-T cell therapy in which programmed cell death protein 1 (“PD-1”) has been removed from the CAR-T cell surface by a genome-edited knockout of the PDCD1 gene, which is said to distinguish CB-010 from other allogeneic CAR-T cells by, among other things, improving the “persistence” of antitumor activity.

On July 1, 2021, Caribou filed a registration statement on Form S-1 with the SEC in connection with the IPO, which, after several amendments, was declared effective by the SEC on July 22, 2021 (the “Registration Statement”).

On July 23, 2021, Caribou’s common stock began public trading pursuant to its registration statement on the Nasdaq Global Select Market (“NASDAQ”) under the ticker symbol “CRBU.” On the same day, Caribou submitted a…